PLX

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Performance in Q1 was primarily driven by a $25 million milestone payment from Chiesi following the European Commission's approval of Elfabrio's every 4 weeks dosing regimen. The new every 4 weeks dosing flexibility in Europe is expected to reduce treatment burden for patients, strengthening Elfabrio's competitive position and supporting broader adoption over time. Management attributes the decrease in selling goods revenue to timing and inventory dynamics regarding Elelyso purchases by Pfizer and Fiocruz, rather than a shift in underlying demand. The company is focusing its long-term strategy on rare renal diseases, believing its platform offers a clear advantage and a business model that limits downside risk while preserving clinical upside. Management maintains a long-term target of 15% to 20% global market share for Elfabrio by 2031, supported by a projected $3.2 billion total addressable market. Reaffirmed 2026 total revenue guidance of approximately $78 million to $83 million, which includes the $25 million milestone already received. The company expects Elfabrio product revenues to range between $33 million and $35 million for the full year, with growth weighted toward the second half of 2026. The Phase II RELEASE study for PRX-115 is expected to complete enrollment by the end of 2026, with top-line results anticipated in the second half of 2027. Management intends to provide specific indication details for the PRX-119 program by the end of the current quarter to clarify the clinical development path. The company ended the quarter with $51 million in cash and no outstanding debt or warrants, which management states provides sufficient funds for the Phase II RELEASE study. R&D expenses increased to $5.4 million from $3.5 million year-over-year, reflecting a deliberate capital allocation shift toward the PRX-115 clinical program. Net income reached $18.3 million for the quarter, a significant shift from a prior year loss, though this was heavily influenced by the one-time milestone revenue. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management expects the second half of 2026 to be stronger for Elfabrio sales as Chiesi navigates country-by-count...

This article first appeared on GuruFocus. Release Date: May 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Protalix BioTherapeutics Inc (PLX) received a $25 million milestone payment following the European Commission's approval of El Fabrio's every four weeks dosing regimen. The company ended the first quarter with $51 million in cash, providing a strong balance sheet and substantial financial flexibility. Protalix BioTherapeutics Inc (PLX) reaffirmed its 2026 revenue guidance, expecting total revenue to range from $78 million to $83 million. The company is actively enrolling for the PRX-115 Phase II release study, with top-line results expected in the second half of 2027. Protalix BioTherapeutics Inc (PLX) operates a profitable commercial business, with net income for the quarter at $18.3 million, compared to a net loss in the prior year period. Revenues from selling goods decreased to $7.4 million from $10 million in the first quarter of 2025, reflecting lower purchases by Pfizer. R&D expenses increased to $5.4 million, up from $3.5 million in the prior year period, driven by the PRX-115 Phase 2 release study. SG&A expenses rose to $3.1 million, reflecting modest growth year-over-year, largely due to personnel-related costs. The company has not provided specific updates on the progress of enrollment for the PRX-115 Phase II release study. Initial data or insights into the market uptake of El Fabrio's every four weeks dosing regimen are not yet available, with expectations of seeing results in the second half of the year. Warning! GuruFocus has detected 5 Warning Signs with PLX. Is PLX fairly valued? Test your thesis with our free DCF calculator. Q: Can you comment on the expected revenue cadence from Chiesi regarding El Fabrio's sales and the likelihood of increasing the full-year 2026 guidance for El Fabrio-related royalty-based revenue? A: We received approval for the four-week dosing regimen on March 5th, and Chiesi is now working on obtaining local reimbursement approvals country by country. We expect to see the impact mostly in the second half of the year and are maintaining our current guidance. Q: How is enrollment progressing in the PRX-115 release trial, and when do you expect to complete enrollment? A: Enrollment is progressing with many sites open. We aim to complete enrollment by th...

Protalix BioTherapeutics (AMEX:PLX) released first-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more. View the webcast at https://viavid.webcasts.com/starthere.jsp?ei=1762414&tp_key=330c698581 Protalix BioTherapeutics reported a $25 million milestone payment from Chiesi due to European Commission approval of a new dosing regimen for El Fabrio, ending the quarter with $51 million in cash. The company reaffirmed its 2026 revenue guidance of $78 to $83 million, with key revenue drivers being El Fabrio and PRX115's Phase 2 study and ongoing partnerships. The company plans to capture 15-20% of the global Fabry market by 2031, with strategic focus on expanding El Fabrio's presence in Europe and advancing PRX115 for uncontrolled gout. First-quarter revenue was $33.8 million, with an increase in R&D expenses to $5.4 million due to the PRX115 Phase 2 study, while maintaining a strong financial position with no debt. Management expressed confidence in achieving long-term growth through strategic partnerships and pipeline advancement, with expectations for significant revenue growth in the second half of 2026. OPERATOR . Good morning ladies and gentlemen and welcome to Protalix BioTherapeutics First Quarter 2026 Financial and Business Results Conference Call. As a reminder, this conference is being recorded. I will now turn the conference over to our host, Mr. Mike Moyer of LASCI Advisors, Investor Relations for Protalix. Thank you. Please go ahead. Mike Moyer (Investor Relations) Thank you Operator and welcome to Protalix BioTherapeutics Q1 2026 financial results and Business Update Conference Call. With me today are Dror Bashan, President and CEO of Protalix, and Gilad Mamlach, Senior Vice President and Chief Financial Officer. A press release announcing the financial results and corporate updates were issued this morning and are available now on the Protalix website. Please take a moment to read the disclaimer about forward looking statements in the press release. The earnings release and this teleconference include forward looking statements. These forward looking statements are subject to known and unknown risks and uncertainties. They may cause actual results to differ mate...

Company to host conference call and webcast today at 8:00 a.m. EDT Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027 The Company reaffirms its previously stated 2026 revenue guidance of $78.0 – $83.0 million including the $25.0 million milestone received from Chiesi Cash, cash equivalents, and short–term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the Phase 2 RELEASE clinical trial of PRX-115 CARMIEL, Israel, May 13, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the first quarter ended March 31, 2026, and provided a business and clinical update. During the first quarter, the Company continued to execute against its commercial partnerships, advance its clinical and preclinical development programs, and reaffirm its strategic priorities and financial outlook for 2026. "Protalix entered 2026 with positive momentum," said Dror Bashan, President and Chief Executive Officer of Protalix BioTherapeutics. "With the recent regulatory progress for Elfabrio in Europe which triggered the $25 million milestone payment, the continued enrollment of our PRX–115 Phase 2 RELEASE study, and a growing focus on rare renal diseases, we believe the company is entering a pivotal period of growth and clinical advancement. We are confident in our strategy and reaffirm our guidance for 2026. We believe our business model positions us well to generate long–term value while advancing therapies that meaningfully address unmet needs." First Quarter 2026 Operational Update Elfabrio® for Fabry Disease Protalix and its partner, Chiesi Farmaceutici, continue to support the launch and expansion of Elfabrio across approved markets. Following the previously announced European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen, Protalix believes Elfabrio is well-positioned to reduce treatment burden for patients with Fabry disease in t...

HACKENSACK, N.J. (AP) — HACKENSACK, N.J. (AP) — Protalix BioTherapeutics Inc. (PLX) on Wednesday reported earnings of $18.3 million in its first quarter. On a per-share basis, the Hackensack, New Jersey-based company said it had profit of 22 cents. The drug developer posted revenue of $33.8 million in the period. Protalix expects full-year revenue in the range of $78 million to $83 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PLX at https://www.zacks.com/ap/PLX

Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, May 6, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended March 31, 2026 and provide a business update on May 13, 2026. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Details: Date: Wednesday, May 13, 2026 Time: 8:00 a.m. Eastern Daylight Time (EDT) Toll Free: 1-877-423-9813 International: 1-201-689-8573 Israeli Toll Free: 1-809-406-247 Conference ID: 13760475 Call me™: https://tinyurl.com/yjww2vxn The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away. Webcast Details: The conference will be webcast live from the Protalix website and will be available via the following links: Company Link: https://ir.protalix.com/news-events/events Webcast Link: https://tinyurl.com/ykmy9jmr Conference ID: 13760475 Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website at the above link. About Protalix BioTherapeutics, Inc. Protalix is a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases. Protalix has researched, developed, and currently manufactures two enzyme replacement therapies that are currently available in multiple markets. These therapies are recombinant therapeutic proteins expressed through Protalix's proprietary plant cell-based expression system, ProCellEx®. ProCellEx is a unique plant cell-based system that enables Protalix to produce recombinant proteins in an industrial-scale manner with no exposure to mammalian cells. Protalix is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix has...

Pluxee delivers strong margin expansion and cash generation in H1 Fiscal 2026, reaffirming all full‑year objectives Highlights Robust commercial traction in H1 Fiscal 2026 on track with full-year plan, supported by record new client acquisition, rising face value and steady cross-selling €655m Total Revenues, up +5.6% organically, including: €573m Operating revenue, up +5.7% organically, including core Employee Benefits growing strongly by +9.4% organically €81m Float revenue, up +5.3% organically 37.0% Recurring EBITDA margin, up +229bps on an organic basis, +159bps reported year-on-year, translating into €242m Recurring EBITDA, up +12.9% organically €105m Net profit, Group share up +7.8% year-on-year; €0.78 Adjusted earnings per share, Group share, up +6.8% €210m Recurring free cash flow delivering 86% Recurring cash conversion rate and strengthening Group's Net financial cash position to €1,270m as of February 28, 2026 Fiscal 2026 financial objectives confirmed, reflecting the Group's confidence in its operating and financial trajectory amid macroeconomic and geopolitical uncertainty, and factoring in the impacts of regulatory developments in Brazil from Second Half Fiscal 2026 First Half Fiscal 2026 key figures (1) Attributable to the equity holders of the parent. (2) First Half Fiscal 2026 corresponds to the Net financial cash position as of February 28, 2026, and First Half Fiscal 2025 corresponds to the Net financial cash position as of August 31, 2025. Aurélien Sonet, Chief Executive Officer of Pluxee, commented: "This first‑half performance continued to highlight the strength of Pluxee’s business model and the discipline of our execution. In an increasingly challenging macroeconomic and geopolitical environment, our teams have delivered with consistency and agility across markets, driving strong commercial performance and financial results. I would like to sincerely thank them for their continued commitment and dedication. Our core Employee Benefit business continued to act as the Group's growth engine over the semester, underpinning a solid topline trajectory and confirming the relevance of our offering at a time when employees' purchasing power as well as their health and well‑being are critical priorities for our clients. In parallel, the Group kept on delivering solid financial performance, with further meaningful progress in profitability and c...

Regulated information Paris, April 13, 2026 DISCLOSURE FISCAL 2026/23 OF TRANSACTIONS ON TREASURY SHARES Period of: April 7 to April 10, 2026 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49) Aggregate presentation by day and by market. About Pluxee Pluxee is a global player in Employee Benefits and Engagement that operates in 28 countries. Pluxee helps companies attract, engage, and retain talent thanks to a broad range of solutions across Meal & Food, Well-being, Lifestyle, Reward & Recognition, and Public Benefits. Powered by leading technology and more than 5,600 engaged team members, Pluxee acts as a trusted partner within a highly interconnected B2B2C ecosystem made up of more than 500,000 clients, 37 million+ consumers and 1.7 million+ merchants. Conducting business for more than 45 years, Pluxee is committed to creating a positive impact on local communities, supporting well-being at work for employees and protecting the planet. For more information: www.pluxeegroup.com Contacts Attachment PR PLUXEE_DISCLOSURE 2026.23 OF TRANSACTIONS ON TREASURY SHARES

Regulated information Paris, April 7, 2026 DISCLOSURE FISCAL 2026/22 OF TRANSACTIONS ON TREASURY SHARES Period of: March 30 to April 2, 2026 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49) Aggregate presentation by day and by market. About Pluxee Pluxee is a global player in Employee Benefits and Engagement that operates in 28 countries. Pluxee helps companies attract, engage, and retain talent thanks to a broad range of solutions across Meal & Food, Well-being, Lifestyle, Reward & Recognition, and Public Benefits. Powered by leading technology and more than 5,600 engaged team members, Pluxee acts as a trusted partner within a highly interconnected B2B2C ecosystem made up of more than 500,000 clients, 37 million+ consumers and 1.7 million+ merchants. Conducting business for more than 45 years, Pluxee is committed to creating a positive impact on local communities, supporting well-being at work for employees and protecting the planet. For more information: www.pluxeegroup.com Contacts Attachment PR PLUXEE_DISCLOSURE 2026.22 OF TRANSACTIONS ON TREASURY SHARES

Regulated information Paris, March 30, 2026 DISCLOSURE FISCAL 2026/21 OF TRANSACTIONS ON TREASURY SHARES Period of: March 23 to March 27, 2026 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49) Aggregate presentation by day and by market. About Pluxee Pluxee is a global player in Employee Benefits and Engagement that operates in 28 countries. Pluxee helps companies attract, engage, and retain talent thanks to a broad range of solutions across Meal & Food, Well-being, Lifestyle, Reward & Recognition, and Public Benefits. Powered by leading technology and more than 5,600 engaged team members, Pluxee acts as a trusted partner within a highly interconnected B2B2C ecosystem made up of more than 500,000 clients, 37 million+ consumers and 1.7 million+ merchants. Conducting business for more than 45 years, Pluxee is committed to creating a positive impact on local communities, supporting well-being at work for employees and protecting the planet. For more information: www.pluxeegroup.com Contacts Attachment PR PLUXEE_DISCLOSURE 2026.21 OF TRANSACTIONS ON TREASURY SHARES

Regulated information Paris, March 23, 2026 DISCLOSURE FISCAL 2026/20 OF TRANSACTIONS ON TREASURY SHARES Period of: March 16 to March 20, 2026 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49) Aggregate presentation by day and by market. About Pluxee Pluxee is a global player in Employee Benefits and Engagement that operates in 28 countries. Pluxee helps companies attract, engage, and retain talent thanks to a broad range of solutions across Meal & Food, Well-being, Lifestyle, Reward & Recognition, and Public Benefits. Powered by leading technology and more than 5,600 engaged team members, Pluxee acts as a trusted partner within a highly interconnected B2B2C ecosystem made up of more than 500,000 clients, 37 million+ consumers and 1.7 million+ merchants. Conducting business for more than 45 years, Pluxee is committed to creating a positive impact on local communities, supporting well-being at work for employees and protecting the planet. For more information: www.pluxeegroup.com Contacts Attachment PR PLUXEE_DISCLOSURE 2026.20 OF TRANSACTIONS ON TREASURY SHARES